CEBPZ

CCAAT/enhancer-binding protein zeta · Q03701 · CEBPZ on Sugi Atlas →

0 patent compounds predicted against CEBPZ, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CEBPZ by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanisms of Lipodystrophy in HIV-Infected Pateints PHASE4COMPLETED
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes PHASE4COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease PHASE1/PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant PHASE2COMPLETED
Efficacy and Safety of Oltipraz in the Patients With Liver Fibrosis and Cirrhosis PHASE2COMPLETED
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia nanCOMPLETED
3mg Liraglutide for Overweight or Obesity nanCOMPLETED
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients nanUNKNOWN
Quantification of GADD34 Expression in RA nanCOMPLETED
Detection of Krupple Like Factor -1(KLF1/ EKLF) DNA Mutations in Beta Thalassemia Patients nanNOT_YET_RECRUITING
Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia nanCOMPLETED
Study of Proteins in Head and Neck Cancer Cells nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients nanUNKNOWN
A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome nanCOMPLETED
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone. nanCOMPLETED
EKLF Gene Expression in β-thalassemia nanNOT_YET_RECRUITING
RORC Genetic Polymorphism of Rheumatoid Arthritis nanCOMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Thermogenic Silencer Regulatory Factors in Humans nanACTIVE_NOT_RECRUITING
Card14gene (rs34367357 ) Polymorphism in Egyptian Psoriatic and Psoriatic Arthritis Patient nanRECRUITING
Oxidative Stress in Intestinal Metaplasia and Metabolic Syndrome nanUNKNOWN
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CEBPZ binder may also engage these)

ProteinNameSimilarity
P53569 1.000 P53569 →
O36021 0.994 O36021 →
F4IDJ0 0.993 F4IDJ0 →
F4IDC2 0.993 F4IDC2 →
Q2VPG3 0.992 Q2VPG3 →
Q80UZ2 0.992 Q80UZ2 →
Q6NV26 0.991 Q6NV26 →
A5D7C2 0.991 A5D7C2 →
Q19753 0.990 Q19753 →
Q9VTE6 0.990 Q9VTE6 →
A4IIB1 0.990 A4IIB1 →
Q7KKH3 0.989 Q7KKH3 →
Q28E45 0.989 Q28E45 →
Q8VI84 0.989 Q8VI84 →
Q6DRN3 0.989 Q6DRN3 →
Q9ERA6 0.988 Q9ERA6 →
Q9VIF0 0.988 Q9VIF0 →
Q12176 0.988 Q12176 →
Q9ZPV5 0.988 Q9ZPV5 →
Q5XGZ8 0.988 Q5XGZ8 →
A7S6A5 0.988 A7S6A5 →
E1C760 0.988 E1C760 →
Q10342 0.988 Q10342 →
Q8WTT2 0.988 Q8WTT2 →
Q5XIQ5 0.988 Q5XIQ5 →
Q5R952 0.987 Q5R952 →
A1XD95 0.987 A1XD95 →
Q5R5K8 0.987 Q5R5K8 →
F7AEX0 0.987 F7AEX0 →
A1XD94 0.987 A1XD94 →